The document provides an overview of Targovax's clinical programs for ONCOS-102 and TG01. For ONCOS-102, a Phase I/II trial in ovarian and colorectal cancer in combination with durvalumab was initiated in Q3 2017. Encouraging survival and immune response data was reported from the ongoing Phase I/II trial of TG01 in resected pancreatic cancer. Targovax is developing these programs to boost the effectiveness of immunotherapy and has clinical readouts expected in 2017-2019.
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
Targovax presented highlights from Q1 2017, including encouraging survival data from a phase I/II trial of TG01 in pancreatic cancer. 68% of patients were still alive after 2 years, compared to historical rates of 30-53%. Targovax will present further clinical data on TG01 at ASCO in June. The company initiated an exploratory trial of TG01 in colorectal cancer and has six clinical trials ongoing or planned in 2017-2018 across cancer indications. Financially, Targovax has cash of NOK 147M and an operating expenses run rate of NOK 104M annually based on the last four quarters.
Targovax presented its 3Q 2017 results, highlighting ongoing clinical trials with its two platforms: ONCOS-102, an oncolytic virus in Phase I/II trials in combination with other therapies, and TG01, a neoantigen vaccine showing encouraging survival data in a Phase I/II trial in pancreatic cancer. Targovax has a cash runway into 2019 to fund its clinical programs and is listed on the Oslo Stock Exchange with a market capitalization of around NOK 930 million.
Targovax is developing two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide vaccine targeting RAS mutations. Early phase clinical trial data shows promise for both platforms. ONCOS-102 increased tumor-infiltrating CD8+ T-cells in 11 of 12 cancer patients and induced systemic anti-tumor immune responses. TG01 shows a median survival of 33.1 months in a phase I/II pancreatic cancer trial compared to historical controls of 27.6 months. Targovax has initiated six new clinical trials to further evaluate these platforms alone and in combination with other therapies.
Targovax is developing immunotherapies to enable the immune system to kill cancer cells. They have two platforms: oncolytic viruses and peptide vaccines. Their peptide vaccine TG01 showed encouraging 2-year survival data in a Phase I/II trial in pancreatic cancer patients, with a survival rate higher than historical controls. Their oncolytic virus ONCOS-102 is in a Phase I trial in CPI-refractory melanoma patients to see if it can activate the immune system and make those patients responsive to checkpoint inhibitors again. Targovax has multiple clinical readouts expected in 2017 and 2018 that could be value inflection points.
This document provides an overview of Targovax, a biotechnology company developing immunotherapy treatments for cancer. It summarizes Targovax's two platform technologies: ONCOS-102, an oncolytic virus that selectively infects and lyses cancer cells to trigger an immune response, and TG neoantigen vaccines that target specific cancer mutations to generate T-cells to kill cancer cells. The document outlines Targovax's clinical development plans and timelines across six clinical trials in several cancer indications. It also reviews the company's financial position and shareholder base, noting a strong cash runway into 2019 to complete the planned clinical program.
This document provides an overview of Targovax, a biotech company developing immunotherapies for cancer. It summarizes their two platforms: ONCOS-102, an oncolytic virus, and TG, a neoantigen cancer vaccine targeting RAS mutations. For ONCOS-102, phase 1 data showed it can activate the immune system against tumors. Targovax is conducting multiple clinical trials of ONCOS-102 in combination with other therapies. For TG, earlier phase 1 trials showed a 20% 10-year survival rate in pancreatic cancer patients. A recent phase 1/2 trial in pancreatic cancer showed encouraging survival and safety data. Targovax is seeking a partner to advance TG into a
Targovax has two immuno-oncology programs - ONCOS, an oncolytic virus, and TG, a RAS neoantigen vaccine. TG has shown promising results in pancreatic cancer trials, with 20% 10-year survival in previous trials. An ongoing phase I/II trial is validating these results with adjuvant chemotherapy. ONCOS has demonstrated the ability to increase tumor-infiltrating T-cells in early trials. Targovax has a broad clinical program with several upcoming data readouts in 2017-2018 from trials in melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic/colorectal cancers.
Targovax is developing immunotherapies to help the immune system fight cancer. They have six ongoing clinical trials combining their oncolytic adenovirus or peptide vaccines with checkpoint inhibitors or chemotherapy. They expect readouts from four of these trials in 2017-2018, which will be important value inflection points. Encouraging survival data was seen in a Phase I/II trial of their peptide vaccine TG01 in resected pancreatic cancer patients.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
The document discusses Targovax's TG01 peptide vaccine platform. TG01 primes the immune system to recognize and destroy cancer cells with RAS mutations through a cocktail of 7 peptides covering common RAS mutations. Earlier trials in pancreatic cancer showed encouraging median and 1-year survival rates compared to historical controls when TG01 was administered with GM-CSF adjuvant. Long-term survival data also correlated with immune responses detected following vaccination.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
Arming the patient's immune system to fight cancertargovax2017
This document summarizes a presentation by Targovax CEO Øystein Soug at a healthcare conference on December 15, 2016. Targovax is developing immunotherapies to enable the immune system to kill cancer cells, including oncolytic viruses, peptide vaccines, cell therapies, and checkpoint inhibitors. The presentation outlines Targovax's clinical trial pipeline and strategy, including trials of ONCOS-102 in CPI-refractory melanoma and mesothelioma and TG01 in resected pancreatic and colorectal cancers. Near-term value drivers include TG01 two-year survival data in pancreatic cancer in 1H2017 and ONCOS-102 interim data in melanoma in 2H2017.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
This document provides an overview of Targovax's clinical programs for their two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For TG, encouraging survival data was seen in a previous trial in resected pancreatic cancer patients, with 20% 10-year survival. This is now being validated in an ongoing phase I/II trial, with 90% of patients showing immune activation against RAS. For ONCOS, phase I data showed it increased tumor-infiltrating CD8+ T-cells and this correlated with improved survival. In mouse models, ONCOS enhanced the efficacy of checkpoint inhibitors against melanoma. Targovax has an ongoing clinical program with these
- Targovax has developed a peptide vaccine called TG01 that targets RAS mutations found in over 90% of pancreatic cancers.
- In clinical trials, TG01 has shown an ability to induce both CD4+ and CD8+ T-cell immune responses against mutant RAS in over 90% of patients. Patients who responded immunologically showed a 3x longer median survival time.
- Interim data from an ongoing Phase I/II trial combining TG01 with chemotherapy in resected pancreatic cancer patients showed 100% 1-year survival for the second cohort and a median survival of 33.1 months, compared to a historical control of 27.6 months.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
The document provides an overview and highlights from Targovax's first quarter 2018 presentation. Some key points:
- Targovax has two immuno-oncology programs in clinical development, ONCOS-102 and ONCOS TG.
- In the mesothelioma trial, the safety lead-in cohort of 6 patients was completed without safety concerns and showed signs of immune activation and early clinical responses in 3 patients.
- Targovax has a sound financial position with cash to fund its planned clinical program into 2019 and is listed on the Oslo Stock Exchange.
1) The document discusses Targovax's clinical programs targeting cancer through immune activation, including their ONCOS oncolytic virus and TG RAS neoantigen vaccine.
2) Early clinical trials of ONCOS-102 demonstrated immune activation and clinical activity in patients with various solid tumors.
3) Targovax is conducting additional trials of ONCOS-102 in combination with checkpoint inhibitors in indications like mesothelioma and peritoneal cancers.
4) The TG vaccine targets mutated RAS neoantigens, which are present in many cancer types, and aims to induce T-cell responses against patient-specific tumors.
Targovax has two immuno-oncology programs in clinical development - ONCOS and TG. For ONCOS, clinical trials are ongoing in melanoma, mesothelioma, and other solid tumors. Data from the melanoma trial showed ONCOS-102 induced immune activation in the first four patients. The mesothelioma trial safety lead-in was completed without concerns. For TG, clinical data in pancreatic cancer showed one-year survival rates and immune activation. Targovax is listed on the Oslo Stock Exchange with a market capitalization of around NOK 900 million and cash reserves to fund the planned clinical program into 2019.
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
This report discusses Targovax's oncolytic virus and neoantigen vaccine programs for cancer immunotherapy. ONCOS-102, an oncolytic virus, has shown signs of efficacy in early clinical trials and is being studied in combination with chemotherapy for mesothelioma. Targovax is also developing TG, a neoantigen vaccine targeting mutated RAS cancers which accounts for many pancreatic and colorectal cancer cases. Targovax has an ongoing clinical program and aims to become a frontline treatment for mesothelioma with ONCOS-102 based on positive early data.
Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
Targovax provides a summary of their company presentation on activating the immune system to fight cancer. They have two clinical programs, ONCOS oncolytic virus and TG neoantigen vaccine. ONCOS has ongoing clinical trials in mesothelioma, melanoma, ovarian and colorectal cancers. Early results show immune activation and clinical activity. Their focus is developing ONCOS as the lead product, with mesothelioma as the potential initial indication due to its orphan drug designation. Financially, Targovax has sufficient cash into the second half of 2019 to complete their planned clinical program.
This document discusses Targovax's strategy for outsourcing clinical manufacturing and quality control activities. As a virtual biotech company, Targovax outsources all development, manufacturing, and testing of its three investigational medicinal products - a peptide vaccine (TG), recombinant GM-CSF, and an oncolytic virus (ONCOS-102). The document describes Targovax's current contract manufacturing organizations for clinical supply and its plans to select new partners to support late-stage clinical trials and commercialization. It provides an overview of Targovax's multi-stage process for evaluating and selecting these strategic contract development and manufacturing partners.
Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
Targovax Next generation immune activators for solid tumorsRoarFredriksen1
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
Building on successful clinical studies which have provided deep mechanistic insights into the tumor biology and the human immune systems, Targovax is researching circular RNA (circRNA) as novel cancer medicines. In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, expected to enter the clinic in an enhanced format in the second half of 2022. Together this provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.
This document discusses Targovax's focus on immune activators to treat cancer. It summarizes:
1) Targovax's approach of using oncolytic viruses and vaccines to activate T-cells to target tumors, rather than directly targeting cancer through surgery, radiation, or chemotherapy.
2) Targovax's two programs - ONCOS, an oncolytic virus, and TG, a therapeutic cancer vaccine - and their clinical development strategies.
3) Early positive results from a Phase I/II trial of ONCOS-102 for malignant pleural mesothelioma, with the drug showing safety, innate and adaptive immune activation, and early signs of clinical activity.
Targovax presentation december 2017 carnegietargovax2017
Targovax provided an overview of its clinical programs for its two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For ONCOS, interim data from ongoing phase I/II trials in several solid tumors was highlighted. For TG, encouraging survival data from a phase I/II trial in resected pancreatic cancer was summarized. Upcoming clinical readouts and trial initiations in 2017-2018 were outlined for both platforms.
1706 ir deck full w_appendix v1_cmd_v12_netttargovax2017
The document discusses Targovax's TG01 peptide vaccine platform. TG01 primes the immune system to recognize and destroy cancer cells with RAS mutations through a cocktail of 7 peptides covering common RAS mutations. Earlier trials in pancreatic cancer showed encouraging median and 1-year survival rates compared to historical controls when TG01 was administered with GM-CSF adjuvant. Long-term survival data also correlated with immune responses detected following vaccination.
Targovax is developing two cancer immunotherapy drugs - ONCOS-102, an oncolytic virus, and TG01, a neoantigen vaccine. Data from clinical trials of ONCOS-102 showed it activated patients' immune systems against their tumors. Targovax has an ongoing clinical program testing ONCOS-102 in various cancer types and combinations. TG01 targets RAS mutations in pancreatic cancer and showed encouraging long-term survival rates in previous trials. A recent trial combining TG01 with chemotherapy showed improved median and 2-year survival over historical controls. Targovax is seeking a partner to advance TG01 into a late-stage trial aimed at registration.
1706 ir deck full w_appendix v1_cmd_v6_uten appendixtargovax2017
The document summarizes a capital markets update presentation by Targovax. It discusses Targovax's two immunotherapy platforms - ONCOS-102, an oncolytic virus, and TG01, a peptide cancer vaccine. For ONCOS-102, the virus is injected into tumors where it stimulates an immune response by releasing cancer antigens. TG01 mimics antigens to stimulate "killer" T-cells. Early clinical trial results for ONCOS-102 showed increased tumor-infiltrating T-cells and systemic immune responses in cancer patients. Targovax is pursuing multiple clinical trials to combine its immunotherapies with other treatments.
Arming the patient's immune system to fight cancertargovax2017
This document summarizes a presentation by Targovax CEO Øystein Soug at a healthcare conference on December 15, 2016. Targovax is developing immunotherapies to enable the immune system to kill cancer cells, including oncolytic viruses, peptide vaccines, cell therapies, and checkpoint inhibitors. The presentation outlines Targovax's clinical trial pipeline and strategy, including trials of ONCOS-102 in CPI-refractory melanoma and mesothelioma and TG01 in resected pancreatic and colorectal cancers. Near-term value drivers include TG01 two-year survival data in pancreatic cancer in 1H2017 and ONCOS-102 interim data in melanoma in 2H2017.
Targovax is developing cancer immunotherapies using their TG technology to arm the immune system to fight RAS mutated cancers. Their lead candidate TG01 is in Phase I/II trials in combination with chemotherapy for resected pancreatic cancer, showing promising early survival data. Targovax has a broad clinical program with upcoming data readouts evaluating TG01 in additional cancer types and TG02 entering Phase I trials. Their therapeutic cancer vaccines target specific RAS mutations found in many cancers, offering a potential new treatment approach.
Targovax is developing two complementary and highly targeted approaches to cancer immunotherapy: a peptide-based targeted immunotherapy platform for patients with RAS-mutated cancers and a virus-based oncolytic immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors.
This document provides an overview of Targovax's clinical programs for their two immuno-oncology platforms: ONCOS oncolytic virus and TG mutRAS neoantigen vaccine. For TG, encouraging survival data was seen in a previous trial in resected pancreatic cancer patients, with 20% 10-year survival. This is now being validated in an ongoing phase I/II trial, with 90% of patients showing immune activation against RAS. For ONCOS, phase I data showed it increased tumor-infiltrating CD8+ T-cells and this correlated with improved survival. In mouse models, ONCOS enhanced the efficacy of checkpoint inhibitors against melanoma. Targovax has an ongoing clinical program with these
- Targovax has developed a peptide vaccine called TG01 that targets RAS mutations found in over 90% of pancreatic cancers.
- In clinical trials, TG01 has shown an ability to induce both CD4+ and CD8+ T-cell immune responses against mutant RAS in over 90% of patients. Patients who responded immunologically showed a 3x longer median survival time.
- Interim data from an ongoing Phase I/II trial combining TG01 with chemotherapy in resected pancreatic cancer patients showed 100% 1-year survival for the second cohort and a median survival of 33.1 months, compared to a historical control of 27.6 months.
1708 2 q presentation v6 uten back-upstargovax2017
This document provides a 3-sentence summary of a presentation by Targovax, a biotech company developing immunotherapies to treat cancer:
Targovax is developing two immunotherapy platforms, ONCOS-102 oncolytic virus and TG01 RAS peptide vaccine, to boost immune responses against cancer and has clinical trials ongoing or planned in several cancer types including pancreatic, melanoma, mesothelioma and others.
The presentation highlights interim clinical data from TG01 showing improved survival outcomes compared to historical controls in resected pancreatic cancer patients and outlines the company's clinical development plans and timelines over the next two years with multiple data readouts expected.
Targovax has sufficient cash runway into
The document provides an overview and highlights from Targovax's first quarter 2018 presentation. Some key points:
- Targovax has two immuno-oncology programs in clinical development, ONCOS-102 and ONCOS TG.
- In the mesothelioma trial, the safety lead-in cohort of 6 patients was completed without safety concerns and showed signs of immune activation and early clinical responses in 3 patients.
- Targovax has a sound financial position with cash to fund its planned clinical program into 2019 and is listed on the Oslo Stock Exchange.
1) The document discusses Targovax's clinical programs targeting cancer through immune activation, including their ONCOS oncolytic virus and TG RAS neoantigen vaccine.
2) Early clinical trials of ONCOS-102 demonstrated immune activation and clinical activity in patients with various solid tumors.
3) Targovax is conducting additional trials of ONCOS-102 in combination with checkpoint inhibitors in indications like mesothelioma and peritoneal cancers.
4) The TG vaccine targets mutated RAS neoantigens, which are present in many cancer types, and aims to induce T-cell responses against patient-specific tumors.
Targovax has two immuno-oncology programs in clinical development - ONCOS and TG. For ONCOS, clinical trials are ongoing in melanoma, mesothelioma, and other solid tumors. Data from the melanoma trial showed ONCOS-102 induced immune activation in the first four patients. The mesothelioma trial safety lead-in was completed without concerns. For TG, clinical data in pancreatic cancer showed one-year survival rates and immune activation. Targovax is listed on the Oslo Stock Exchange with a market capitalization of around NOK 900 million and cash reserves to fund the planned clinical program into 2019.
This document summarizes Targovax's approach to activating the immune system to fight cancer. It discusses moving from sequential treatment strategies like surgery, radiation, and chemotherapy to a combination approach harnessing the immune system. Targovax's focus is on immune activators like oncolytic viruses and vaccines to make cancer visible to the immune system. The document outlines Targovax's clinical programs using oncolytic viruses ONCOS and therapeutic cancer vaccine TG, including current and planned trials in cancers like mesothelioma, melanoma, and colorectal cancer. Early data from a phase I/II trial of ONCOS-102 in mesothelioma shows safety and signs of efficacy.
1) The document discusses Targovax's clinical programs using oncolytic viruses and neoantigen vaccines to activate a patient's immune system to fight cancer.
2) Targovax has two lead programs - ONCOS, an oncolytic virus, and TG, a neoantigen vaccine. ONCOS has several ongoing clinical trials and TG has one ongoing trial in colorectal cancer.
3) Preliminary data from a TG trial in pancreatic cancer showed increased median overall and disease-free survival compared to historical controls, suggesting efficacy.
This report discusses Targovax's oncolytic virus and neoantigen vaccine programs for cancer immunotherapy. ONCOS-102, an oncolytic virus, has shown signs of efficacy in early clinical trials and is being studied in combination with chemotherapy for mesothelioma. Targovax is also developing TG, a neoantigen vaccine targeting mutated RAS cancers which accounts for many pancreatic and colorectal cancer cases. Targovax has an ongoing clinical program and aims to become a frontline treatment for mesothelioma with ONCOS-102 based on positive early data.
Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
Targovax provides a summary of their company presentation on activating the immune system to fight cancer. They have two clinical programs, ONCOS oncolytic virus and TG neoantigen vaccine. ONCOS has ongoing clinical trials in mesothelioma, melanoma, ovarian and colorectal cancers. Early results show immune activation and clinical activity. Their focus is developing ONCOS as the lead product, with mesothelioma as the potential initial indication due to its orphan drug designation. Financially, Targovax has sufficient cash into the second half of 2019 to complete their planned clinical program.
This document discusses Targovax's strategy for outsourcing clinical manufacturing and quality control activities. As a virtual biotech company, Targovax outsources all development, manufacturing, and testing of its three investigational medicinal products - a peptide vaccine (TG), recombinant GM-CSF, and an oncolytic virus (ONCOS-102). The document describes Targovax's current contract manufacturing organizations for clinical supply and its plans to select new partners to support late-stage clinical trials and commercialization. It provides an overview of Targovax's multi-stage process for evaluating and selecting these strategic contract development and manufacturing partners.
Targovax is a biotechnology company developing oncolytic viruses and cancer vaccines to activate the immune system and fight cancer. The company has two clinical programs, ONCOS-102, an oncolytic virus, and TG, a neoantigen vaccine targeting mutated RAS cancers. Targovax is conducting clinical trials for both programs and has a strong cash position to complete its planned clinical trials into 2019.
Targovax Next generation immune activators for solid tumorsRoarFredriksen1
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax’s focus is to activate the patient’s immune system to fight cancer, and to bring benefit to cancer patients with few available treatment alternatives. Targovax is developing its product candidates in different cancer indications, including melanoma, mesothelioma, and multiple myeloma, and has demonstrated a favorable safety and tolerability profile.
Targovax’s lead clinical candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system against the tumor. Following very encouraging clinical data in several indications, both as monotherapy and in combinations, ONCOS-102 is progressing into a randomized phase 2 trial in melanoma patients resistant to PD-1 checkpoint inhibitor treatment.
Building on successful clinical studies which have provided deep mechanistic insights into the tumor biology and the human immune systems, Targovax is researching circular RNA (circRNA) as novel cancer medicines. In addition, Targovax has a KRAS immunotherapy program, with lead cancer vaccine candidate, TG01, expected to enter the clinic in an enhanced format in the second half of 2022. Together this provides Targovax with a rich pipeline of innovative future immunotherapy product candidates to follow ONCOS-102.
This document discusses Targovax's focus on immune activators to treat cancer. It summarizes:
1) Targovax's approach of using oncolytic viruses and vaccines to activate T-cells to target tumors, rather than directly targeting cancer through surgery, radiation, or chemotherapy.
2) Targovax's two programs - ONCOS, an oncolytic virus, and TG, a therapeutic cancer vaccine - and their clinical development strategies.
3) Early positive results from a Phase I/II trial of ONCOS-102 for malignant pleural mesothelioma, with the drug showing safety, innate and adaptive immune activation, and early signs of clinical activity.
Targovax has two immuno-oncology programs, ONCOS and TG, in clinical development. ONCOS is an oncolytic virus that makes cancer antigens visible to the immune system and induces T-cells specific to patients' tumors. TG is a neoantigen vaccine that targets oncogenic RAS mutations and induces T-cells specific to RAS. Targovax has an ongoing clinical program evaluating these programs in several cancer types including melanoma, mesothelioma, ovarian/colorectal, prostate, and pancreatic cancer. Upcoming data readouts are expected in 2018 from ongoing trials in melanoma, pancreatic cancer, and colorectal cancer.
This corporate presentation summarizes PharmaMar's pipeline and strategy:
- PharmaMar is a biotech company focused on developing marine-derived oncology drugs. It has a fully integrated platform from discovery to commercialization.
- The pipeline includes Yondelis® for soft tissue sarcoma and ovarian cancer, Aplidin® for multiple myeloma, and PM1183 which is being studied in small cell lung cancer, platinum-resistant ovarian cancer, and BRCA breast cancer.
- PM1183 has shown promising results in early clinical trials, achieving a 67% response rate in small cell lung cancer. Phase III trials are ongoing in platinum-resistant ovarian cancer.
This investor presentation summarizes the development of Oncolytics Biotech's lead product REOLYSIN, a therapeutic reovirus. Key points include:
1) REOLYSIN has demonstrated statistically significant improvements in overall survival for metastatic breast cancer and doubled two-year survival for metastatic pancreatic cancer.
2) The clinical development plan focuses on combination therapies with chemotherapy, immunotherapy agents like pembrolizumab, and targeted therapies/IMiDs to boost REOLYSIN's mechanism of action.
3) Over 1,100 patients have been treated with REOLYSIN which has shown a good safety profile with no maximum tolerated dose reached and mostly mild side effects.
An oncology-focused immunotherapy company is conducting a Phase 3 clinical trial of its lead product, NeuVax, for the prevention of breast cancer recurrence in early-stage, node-positive patients. The trial is fully enrolled with 758 participants and is evaluating NeuVax compared to placebo on disease-free survival. NeuVax targets the HER2 protein and consists of an HLA-A2/A3-restricted peptide that elicits CD8+ T-cell responses. Previous clinical trials demonstrated NeuVax has a positive safety profile and signals of efficacy in reducing recurrence rates. An interim analysis is upcoming in mid-2016, with final results expected in 2018.
The document summarizes recent news and events in oncology, including:
1) Daiichi Sankyo's acquisition of Plexxikon for its promising drug PLX4032 that targets the BRAF mutation in melanoma.
2) Positive results from Roche's phase 2 trial of its hedgehog pathway inhibitor vismodegib for advanced basal cell carcinoma.
3) How next-generation sequencing is enabling more personalized cancer treatment by matching drugs to patients based on their tumor's molecular profile.
Download Global cancer immunotherapy market outlook 2020KuicK Research
\"Global Cancer Immunotherapy Market Outlook 2020\" Report Highlight:
Introduction & Classification of Cancer Immunotherapy
Global Cancer Immunotherapy Pipeline by Company, Indication & Phase
Marketed Cancer Immunotherapies Clinical Insight & Patent Analysis by Company & Indication
Global Cancer Immunotherapy Pipeline: 1834 Drugs
Marketed Cancer Immunotherapies: 113 Drugs
Cancer Monoclonal Antibodies Pipeline: 622 Cancer mAb
Cancer Vaccines Pipeline: 312 Vaccines
Marketed Cancer mAb: 36 mAb
Marketed Cancer Vaccines: 12 Vaccines
Global cancer immunotherapy market outlook 2020KuicK Research
The document provides an overview of the global cancer immunotherapy market outlook for 2020. It discusses how cancer immunotherapies work by modulating the immune system to treat cancer. The market has seen significant growth with many approved and pipeline immunotherapies across classes like monoclonal antibodies, cytokines, vaccines, and immune checkpoint inhibitors. The market is expected to continue growing in coming years due to increased research and funding leading to new treatment modalities and biomarkers to expand the use of immunotherapies for additional cancer types.
This investor presentation summarizes Oncolytics Biotech's REOLYSIN viral therapy program. It highlights statistically significant increases in overall survival seen in phase 2 trials in metastatic breast cancer and pancreatic cancer. The clinical development plan focuses on three pathways: chemotherapy combinations as the first registration pathway, immunotherapy combinations with agents like pembrolizumab, and targeted therapy combinations using agents like pomalidomide. Safety data from over 1,100 patients shows a good toxicity profile. Manufacturing is established at commercial scale and the company has a strong patent portfolio. The leadership team has extensive experience in oncology drug development.
Senesco Technologies is developing a gene regulation technology to treat cancer. They are running a Phase 1b/2a clinical trial of their lead product, SNS01-T, to treat B-cell cancers like multiple myeloma and lymphoma. Preclinical studies show SNS01-T significantly inhibits tumor growth and improves survival in mouse models of these cancers. The presentation provides an overview of Senesco's technology, clinical trial status, financial information, and development plans to advance SNS01-T and expand to additional cancer indications.
Oncolytics Biotech presented their investor presentation which included the following key points:
1) Oncolytics is developing REOLYSIN, a novel immuno-oncology viral agent for systemic administration that exploits cancer cell lysis and anti-tumor immunity.
2) Additional randomized phase 2 clinical trials in 2017 are expected to generate overall survival data in breast cancer, ovarian cancer, non-small cell lung cancer, and colorectal cancer.
3) The clinical development plan focuses on combining REOLYSIN with chemotherapy for late-stage development and establishing it as a backbone agent combined with immunotherapy.
4) Over 900 patients have been treated with REOLYSIN intravenously with no drug
Similar to 1711 3 q presentation v7 uten backup (12)
Bienestar Financiero al servicio de su jubilación anticipada
Pago de su 🏡
Estudio de sus hijos
Directamente a tu cuenta bancaria
Con Tesorería Auditoria Jurídica comercial
Administración de carteras
Apalancamiento Financiero
Desarrollo de tu marca personal
Acceso a Desarrollo de varias industrias
Cuentas bancarias
Estructuras Físicas en USA y en América Central
Avalado por Bolcomer
Puesto de Bolsa Comercial
Turismo
Y mucho más
Link de registro
https://business.myinfinity.global/maurod8/
https://therusnetwork.com/
Contacto:
https://goo.su/pzm1fja
UnityNet World Environment Day Abraham Project 2024 Press ReleaseLHelferty
June 12, 2024 UnityNet International (#UNI) World Environment Day Abraham Project 2024 Press Release from Markham / Mississauga, Ontario in the, Greater Tkaronto Bioregion, Canada in the North American Great Lakes Watersheds of North America (Turtle Island).
2. www.targovax.com
Important notice and disclaimer
This report contains certain forward-looking statements based on uncertainty, since they relate to events and
depend on circumstances that will occur in future and which, by their nature, will have an impact on the results of
operations and the financial condition of Targovax. Such forward-looking statements reflect the current views of
Targovax and are based on the information currently available to the company. Targovax cannot give any assurance
as to the correctness of such statements.
There are a number of factors that could cause actual results and developments to differ materially from those
expressed or implied in these forward-looking statements. These factors include, among other things, risks or
uncertainties associated with the success of future clinical trials; risks relating to personal injury or death in
connection with clinical trials or following commercialization of the company’s products, and liability in connection
therewith; risks relating to the company’s freedom to operate (competitors patents) in respect of the products it
develops; risks of non-approval of patents not yet granted and the company’s ability to adequately protect its
intellectual property and know-how; risks relating to obtaining regulatory approval and other regulatory risks relating
to the development and future commercialization of the company’s products; risks that research and development
will not yield new products that achieve commercial success; risks relating to the company’s ability to successfully
commercialize and gain market acceptance for Targovax’s products; risks relating to the future development of the
pricing environment and/or regulations for pharmaceutical products; risks relating to the company’s ability to secure
additional financing in the future, which may not be available on favorable terms or at all; risks relating to currency
fluctuations; risks associated with technological development, growth management, general economic and
business conditions; risks relating to the company’s ability to retain key personnel; and risks relating to the impact of
competition.
2
4. www.targovax.com
Highlights from the third quarter 2017
4
Three posters presented at the ESMO annual meeting in
Madrid - European Society of Molecular Oncology
Reported one-year data for the 2nd cohort in the TG01 ph I/II
trial in resected pancreatic cancer – in line with the 1st cohort
Granted US patent for the 2nd generation product from the TG
platform, TG02
Raised NOK 6.4m (USD 0.8m) in a subsequent offering in July,
following the NOK 200m private placement in June
Granted US patent for the therapeutic use of the TG products
in combination with anti-metabolite chemotherapy
Clinical trials
Initiation of the phase I/II trial with ONCOS-102 in combination
with durvalumab for patients with ovarian and colorectal cancer
Clinical data
Patents
Financing
Post-period
6. www.targovax.com
Immunotherapy has the potential to cure cancer
6
Week 108: complete remission
1 year afterPrior to Yervoy®
Patient example – Yervoy® checkpoint inhibitor trial
IMMUNOTHERAPY
7. www.targovax.com 7
Response rate to checkpoint inhibitors (CPIs)
Complimentary
immune priming
medicines may make
tumors respond
better to checkpoint
inhibitors
~80%
~84%
~80%
~70%
~70%-80%
~40%
Head and Neck
Lung Carcinoma (NSCLC)
Triple Negative Breast
Renal Cell carcinoma
Bladder
Most patients do not respond to currently available
immunotherapies
Non-respondersResponders
Melanoma
IMMUNOTHERAPY
8. www.targovax.com
Targovax is developing two drugs to boost the effect of
immunotherapy
8
ONCOS-102
Oncolytic virus
TG01
Neoantigen vaccine
ONCOS TG
o Cocktail of synthetic peptides targeting oncogenic
RAS mutations
o Generates RAS-specific CD4+ and CD8+ T-cells
o T-cells circulate and identify cancer cells
displaying mutated RAS epitopes
o Encouraging survival data from Phase I/II trials in
pancreatic cancer
o Genetically tailored oncolytic adenovirus
o Selectively infects and lyses cancer cells
o Triggers tumor specific immune response
o Phase I completed and 4 ongoing Phase I/II trials
9. www.targovax.com
Clinical program and upcoming data read-outs
9
Cancer
indication
Combined
with
ONCOS-102
Melanoma CPI
Mesothelioma Chemo* Orphan ind.
Ovarian &
Colorectal
CPI
Orphan ind.
Sponsor: Ludwig
Prostate DC therapy Sponsor: Sotio
TG
Resected
Pancreatic
Chemo* Orphan ind.
Colorectal CPI
4 readouts
2017
5 readouts
2018
2017 2018
H1 H2 H1 H2
2019
H1
Phase l
Phase l/ll
Phase l
Phase lb/ll
Phase I/II
Phase Ib
Interim data Clinical, immune and
safety data
* In combination with Standard of Care Chemoterapy. Pemetrexed/cisplatin for
Mesothelioma and Gemcitabine for Resected Pancreatic
ONCOS TG
Indicative timing of:
11. www.targovax.com
The five year survival rate for pancreatic cancer
patients has not improved since the 1970s
ONCOS TG
No improvement in long-
term survival over the
past 45 years
11
SOURCE: Cancer Research UK, graphic adapted from The Economist September 16 2017
12. www.targovax.com
In earlier trials, TG vaccination has shown 20% 10-year
survival in retrospective analyses
12
ONCOS TG
1 Wedén et al., 2011 2 Oettle H et al., JAMA 2013, vol 310, no 14
0
10
20
30
40
50
60
70
80
90
100
0 6 12 18 24 30 36 42 48 54 60 66 72 78 84 90 96 102 108 114 120
o 4/20 (20%) of treated patients
alive after 10 years
Survival(%)
Months from resection
10 year survival in historical TG trials in resected pancreatic cancer (n=20, TG monotherapy)1
Historical control:
7.7% 10 year survival2
13. www.targovax.com
Targovax was set up to validate the TG concept in a
modern setting with adjuvant chemotherapy
• 32 patients in 2 cohorts
• Single arm design, no
control group
• The cohorts have different
dosing regimens
• Chemo given with/wo TG
• TG booster
injections up to 2
years post surgery
ONCOS TG
Ongoing Phase I/II trial in resected pancreatic cancer with adjuvant Gemcitabine (SoC)
Start of
treatment
1st cohort
2nd cohort
13
14. www.targovax.com
Survival, immune activation and safety data from the
ongoing TG trial is so far very encouraging
14
2nd cohort
(13 patients)
13 of 13 patients (100%) alive 1 year after surgery
mutRAS immune
response (1 yr)
1st cohort 18/19 patients (95%) had immune activation
2nd cohort 11/13 patients (85%) had immune activation
Safety
TG01 and gemcitabine combination treatment is well-tolerated
Four allergic reactions reported in 1st cohort, none in 2nd
cohort (up to 1 year)
1st cohort
(19 patients)
Median survival 33.1 months vs. 27.6 for historical control1
13 of 19 patients (68%) alive 2 years after surgery, historical
control 2 year OS range from 30-53%2
1: Based on ESPAC-4 reported 25.5 months median OS from randomisation, adding median time from surgery to randomization of 64 days (2.1 months)
2: Relevant historical control trials, not including ESPAC-4, which did not report 2 year OS
ONCOS TG
15. www.targovax.com
TG01 data in context
Ref. Prof. Daniel Palmer, London, June 2017
ONCOS TG
Comparative survival rates across trials in resected pancreatic cancer
NOTE: Relative survival curves across studies (ESPAC), meant for indicative comparisons only
15
16. www.targovax.com
Immunological response (DTH) to TG01 is associated with
increased survival in non-resectable pancreatic cancer
Observational study of 25 patients receiving 12 vaccinations during 1 year
Advanced pancreatic cancer
TG01/GM-CSF (mono-therapy)
Evaluable
patients
Median survival
(from 1st
vaccination)
1 year survival
(from 1st
vaccination)
Detected immune response 14 / 25 (56%) 5.2 months 3 (21%)
Not detected Immune response 11 / 25 (44%) 3.6 months 1 ( 9%)
Ref. ESMO 2017
16
ONCOS TG
17. www.targovax.com
Clinical development overview for the TG program
17
Phase I/II
Resected
pancreatic cancer
32 patients
o 10 year survival data
o Correlation between
immune response and
survival
o Large safety database
Colorectal - TG02
Phase I
20 patients
Resected pancreas
TG01 - Phase IIb/III
n = tbd
o TG02, targets 8 mutations
o Combination w/KEYTRUDA®
Currently recruiting patients
o Ph IIb-III adaptive design
o Aimed to reach registration
o Currently seeking
collaboration opportunities
ONCOS TG
Phase I
Resected &
non-resected
>200 patients
Historical trials Planned / recruiting trialsCompleting trial
o Encouraging median
survival
o 3 year survival rate
in 1H 2018
18. www.targovax.com
How TG is different from other peptide vaccine
approaches, and may succeed where others have failed
Target often poorly defined and not
cancer specific
ONCOS TG
Mutated RAS is a well-defined neo-
antigen, and a driving cause of cancer
Lessons Learned The TG approach
Depot-forming adjuvants not
suitable, as activated T-cells return to
depot instead of tumor site
✓
Insufficient immune activation of
CD4+ helper and CD8+ killer T-cells
Non depot-forming immune modulator
GM-CSF used as adjuvant to stimulate
strong, systemic T-cell response
TG peptides are designed and proven
to induce both CD4+ helper and
CD8+ killer mutRAS-specific T-cells
✓
✓
18
20. www.targovax.com
Targovax has initiated a broad clinical program to test the
clinical benefit of ONCOS-102
20
Initial Phase I trial
Solid tumors
7 indications
o 12 refractory patients
o Monotherapy
o Correlation between
immune activation and
survival
Mesothelioma
Phase I/II - controlled
30 patients
Melanoma
Phase I
12 patients
Prostate
Phase I
10 patients
Ovarian / colorectal
Phase I/II - controlled
78 patients
o Combination with PD-1
CPI in refractory patients
o Proof-of-concept
o Memorial Sloan Kettering
o Combination with chemo
o Randomized controlled trial
o Ultra-orphan indication
o Collaboration with Ludwig & CRI
o Combination with Medimmune’s
durvalumab (Imfinzi™)
o Randomized controlled trial
o Partnered with SOTIO
o Combination with DC therapy
Compassionate
use program
Finland
115 patients
o Testing within ATAP
EU program
o Individual clinical
responses
o Reassuring safety
data
ONCOS TG
21. www.targovax.com
Tumor volume reduction vs. vehicle control
% change by Day 40:
ONCOS-102 only 52% reduction
ONCOS-102 + Keytruda (200) 61% reduction
ONCOS-102 + Keytruda (400) 69% reduction
ONCOS TG
ONCOS-102 in melanoma – 70% reduction in tumor
volume with KEYTRUDA® combination in mouse model
Effect of ONCOS-102 and KEYTRUDA® in humanized mouse melanoma model, change in tumor volume
20 30 40
0
100
200
300
400
Days after tumor cells engraftment
Volume(mm3)
(R+L)
Vehicle
OV
Keytruda 200
Keytruda 400
OV+Keytruda 200
OV+Keytruda 400
ONCOS-102
Neg. control
21
22. www.targovax.com
The mouse data support the scientific rationale of the ongoing
clinical melanoma study with ONCOS-102 and KEYTRUDA®
22
CD8+ T-cell
infiltration
ONCOS-102 + KEYTRUDA® >2-fold increase in CD8+ T-cell
count in tumor (vs. neg. control and vs. KEYTRUDA® alone)
KEYTRUDA® alone – no change
Synergistic anti-tumor effect of ONCOS-102 + KEYTRUDA®
ONCOS-102 primes the immune system and enhances
response to KEYTRUDA®
Reduction in
tumor volume
ONCOS-102 + KEYTRUDA® (high) reduced volume by 69%
ONCOS-102 alone reduced tumor volume by 51%
KEYTRUDA® alone did not reduce tumor volume
ONCOS TG
Conclusions
23. www.targovax.com
In Q3, a large trial combining ONCOS-102 and the PD-L1 CPI
durvalumab in ovarian and colorectal cancer was initiated
23
Indication
Ovarian cancer – 42 patients
Colorectal cancer – 36 patients
Safety lead-in – 6 patients
ONCOS TG
Route of
administration
Intraperitoneal administration via catheter
Combination
MedImmune’s PD-L1 checkpoint inhibitor durvalumab
(Imfinzi™)
Partners and
sponsor
Funded by Cancer Research Institute (CRI)
Sponsored by Ludwig Cancer Research
25. www.targovax.com
Targovax has a sound financial position, with cash to
complete the planned clinical program into 2019
Operations
Cash end of Q3 NOK 286m USD 36m Sep 30th 2017
Net cash flow NOK -24m USD -3m Total Q3
Annual run rate NOK 106m USD 13m Last four quarters
25
The share OSE: TRVX
Market Cap NOK 950m USD ~120m At share price NOK ~18
Daily turnover NOK 5m USD 0.6m Rolling 6 month avg.
Analysts DNB, ABG Sundal Collier, Arctic, Redeye, Norske Aksjeanalyser,
Edison
Raised NOK 206 million in private placement June/July 2017
10,000,000 new shares @ NOK 20 per share
CORPORATE
26. www.targovax.com
Targovax is listed on the main board on the Oslo Stock
Exchange, with average daily liquidity of NOK 3.5m
26
Development in daily average share turnover (NOK million / day)*
• NOK ~930 m
market cap
• NOK 3.5m NOK
avg. daily turnover
in last 3 months
• NOK 197m total
turnover in 3Q
• 160k shares avg.
daily volume in 3Q
• >4,800 owners
• 52.6m shares*
(56.2 fully diluted)
* Up until 31th Oct
CORPORATE
Oppdateres etter
fredag
27. www.targovax.com
The shareholder base is strong, with a mix of specialist,
generalist and retail investors
27
CORPORATE
Key international investors participating in PP 2017
– Nyenburgh (NL)
– Trium (UK)
– Millenium Capital Partners (UK)
– Interogo (SWE)
– AP3 (SWE)
– Aramea AM (DE)
Shares and options
▪ 56.2m shares fully diluted
– Average strike price on options ~NOK 21
– Total dilutive effect of options is 6.3%
▪ 52.6m ordinary shares
– Management ownership: 1.7%
– 4,180 shareholders
Shareholder
Shares m Relative
HealthCap Sweden 12,4 23,6 %
Nordea Norway 4,7 8,9 %
RadForsk Norway 4,4 8,4 %
KLP Norway 1,9 3,7 %
Statoil Norway 1,2 2,2 %
Thorendahl Invest AS Norway 0,9 1,7 %
Danske Bank (nom.) Denmark 0,8 1,5 %
Euroclear Bank (nom.) Belgium 0,8 1,4 %
Timmuno Norway 0,7 1,4 %
Prieta AS Norway 0,7 1,4 %
Sundt AS Norway 0,6 1,1 %
Yngve S. Lillesund Norway 0,3 0,6 %
NHO - P665AK Norway 0,3 0,5 %
The Bank of NY Mellon (nom.) Belgium 0,2 0,5 %
The Bank of NY Mellon (nom.) Belgium 0,2 0,4 %
Tobech Invest AS Norway 0,2 0,4 %
Istvan Molnar Norway 0,2 0,4 %
Danske Bank (nom.) Denmark 0,2 0,3 %
Kristian Falnes AS Norway 0,2 0,3 %
Spar Kapital Investor AS Norway 0,2 0,3 %
Top 20 31,0 59,0 %
Other shareholders (4160) 21,6 41,0 %
Total 52,6 100,0 %
Estimated ownership
28. www.targovax.com
Planned strong news flow with multiple near term
value inflection points
28
2015 2016 2017 2018H1 H2
phase ll initiated
TG01
Immune activation
and MoA demo
ONCOS-102
Interim data
pancreas
TG01 (1st cohort)
Immune activation
pancreas
TG01 (2nd cohort)
2-year survival
pancreas
TG01 (1st cohort)
2-year survival
pancreas
TG01 (2nd cohort)
Initiate phase l/ll
mesothelioma
ONCOS-102
Initiate phase l
prostate
ONCOS-102
Initiate phase l/ll
melanoma
ONCOS-102
Interim data
ovarian /colorectal
ONCOS-102
phase l/ll data
melanoma
ONCOS-102
Interim data
melanoma
ONCOS-102
Interim data
mesothelioma
ONCOS-102
Initiate phase Ib in
colorectal
TG02
Interim data
colorectal
TG02 (mono)
Initiate phase l
Ovarian/colorectal
ONCOS-102
Interim data
prostate
ONCOS-102
phase I data/
colorectal
TG02 (combo)
H1 H2
Listing on OSE main
list
Oslo Stock Exchange
FINANCE